Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Press/Media

Period22 Oct 2023 → 23 Oct 2023

Media coverage

10

Media coverage